Compare Capri Holdings Ltd (CPRI) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Citius Pharmaceuticals Inc — how do they compare? Capri Holdings Ltd trades at $14.98 (market cap $1.67B), while Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M). The key difference: Capri Holdings Ltd is far larger — about 122.6× Citius Pharmaceuticals Inc's market cap, and Capri Holdings Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Citius Pharmaceuticals Inc for 17 Days on average.
| CPRI | CTXR | |
|---|---|---|
Market Cap | $1.67B | $13.62M |
Volume | 3,722,279 | 132,438 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $1.82 |
52-Week Low | $12.71 | $0.48 |
Typical Hold Time | 41 Days | 17 Days |
Enterprise Value | $2.95B | $3.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.83, up 2.7% with bullish technical signals and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and positive analyst sentiment (44% buy ratings). However, fundamentals reveal challenges with declining revenue ($4.44B in 2025 vs $5.7B in 2022) and negative net income (-$1.18B), though profitability metrics show improvement potential with 62.7% gross margins.
The outlook balances attractive valuation (P/S 0.51) against turnaround execution risks. Upside exists if brand revitalization succeeds, but investors face headwinds from Michael Kors weakness and competitive pressures. The consensus price target of $20.57 suggests 39% potential upside if recovery gains traction in H2 2026 as management projects.
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
